Global impact and cost-effectiveness of one-dose versus two-dose human papillomavirus vaccination schedules: a comparative modelling analysis.
Cervical cancer
Human papillomavirus
Modelling
Single dose
Vaccination
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
28 08 2023
28 08 2023
Historique:
received:
30
08
2022
accepted:
20
07
2023
medline:
29
8
2023
pubmed:
28
8
2023
entrez:
27
8
2023
Statut:
epublish
Résumé
To eliminate cervical cancer as a public health problem, the World Health Organization had recommended routine vaccination of adolescent girls with two doses of the human papillomavirus (HPV) vaccine before sexual initiation. However, many countries have yet to implement HPV vaccination because of financial or logistical barriers to delivering two doses outside the infant immunisation programme. Using three independent HPV transmission models, we estimated the long-term health benefits and cost-effectiveness of one-dose versus two-dose HPV vaccination, in 188 countries, under scenarios in which one dose of the vaccine gives either a shorter duration of full protection (20 or 30 years) or lifelong protection but lower vaccine efficacy (e.g. 80%) compared to two doses. We simulated routine vaccination with the 9-valent HPV vaccine in 10-year-old girls at 80% coverage for the years 2021-2120, with a 1-year catch-up campaign up to age 14 at 80% coverage in the first year of the programme. Over the years 2021-2120, one-dose vaccination at 80% coverage was projected to avert 115.2 million (range of medians: 85.1-130.4) and 146.8 million (114.1-161.6) cervical cancers assuming one dose of the vaccine confers 20 and 30 years of protection, respectively. Should one dose of the vaccine provide lifelong protection at 80% vaccine efficacy, 147.8 million (140.6-169.7) cervical cancer cases could be prevented. If protection wanes after 20 years, 65 to 889 additional girls would need to be vaccinated with the second dose to prevent one cervical cancer, depending on the epidemiological profiles of the country. Across all income groups, the threshold cost for the second dose was low: from 1.59 (0.14-3.82) USD in low-income countries to 44.83 (3.75-85.64) USD in high-income countries, assuming one dose confers 30-year protection. Results were consistent across the three independent models and suggest that one-dose vaccination has similar health benefits to a two-dose programme while simplifying vaccine delivery, reducing costs, and alleviating vaccine supply constraints. The second dose may become cost-effective if there is a shorter duration of protection from one dose, cheaper vaccine and vaccination delivery strategies, and high burden of cervical cancer.
Sections du résumé
BACKGROUND
To eliminate cervical cancer as a public health problem, the World Health Organization had recommended routine vaccination of adolescent girls with two doses of the human papillomavirus (HPV) vaccine before sexual initiation. However, many countries have yet to implement HPV vaccination because of financial or logistical barriers to delivering two doses outside the infant immunisation programme.
METHODS
Using three independent HPV transmission models, we estimated the long-term health benefits and cost-effectiveness of one-dose versus two-dose HPV vaccination, in 188 countries, under scenarios in which one dose of the vaccine gives either a shorter duration of full protection (20 or 30 years) or lifelong protection but lower vaccine efficacy (e.g. 80%) compared to two doses. We simulated routine vaccination with the 9-valent HPV vaccine in 10-year-old girls at 80% coverage for the years 2021-2120, with a 1-year catch-up campaign up to age 14 at 80% coverage in the first year of the programme.
RESULTS
Over the years 2021-2120, one-dose vaccination at 80% coverage was projected to avert 115.2 million (range of medians: 85.1-130.4) and 146.8 million (114.1-161.6) cervical cancers assuming one dose of the vaccine confers 20 and 30 years of protection, respectively. Should one dose of the vaccine provide lifelong protection at 80% vaccine efficacy, 147.8 million (140.6-169.7) cervical cancer cases could be prevented. If protection wanes after 20 years, 65 to 889 additional girls would need to be vaccinated with the second dose to prevent one cervical cancer, depending on the epidemiological profiles of the country. Across all income groups, the threshold cost for the second dose was low: from 1.59 (0.14-3.82) USD in low-income countries to 44.83 (3.75-85.64) USD in high-income countries, assuming one dose confers 30-year protection.
CONCLUSIONS
Results were consistent across the three independent models and suggest that one-dose vaccination has similar health benefits to a two-dose programme while simplifying vaccine delivery, reducing costs, and alleviating vaccine supply constraints. The second dose may become cost-effective if there is a shorter duration of protection from one dose, cheaper vaccine and vaccination delivery strategies, and high burden of cervical cancer.
Identifiants
pubmed: 37635227
doi: 10.1186/s12916-023-02988-3
pii: 10.1186/s12916-023-02988-3
pmc: PMC10463590
doi:
Substances chimiques
Papillomavirus Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
313Subventions
Organisme : CIHR
ID : FDN-143283
Pays : Canada
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
J Natl Cancer Inst. 2020 Oct 1;112(10):1038-1046
pubmed: 32091594
Cancer. 2008 Nov 15;113(10 Suppl):3036-46
pubmed: 18980286
Lancet Glob Health. 2020 Oct;8(10):e1264-e1272
pubmed: 32687792
NEJM Evid. 2022 Jun;1(5):EVIDoa2100056
pubmed: 35693874
J Natl Cancer Inst. 2020 Feb 1;112(2):145-153
pubmed: 31086947
Lancet Child Adolesc Health. 2020 May;4(5):349-351
pubmed: 32078808
Vaccine. 2010 Apr 19;28 Suppl 1:A54-7
pubmed: 20412998
Vaccine. 2022 Jan 3;40(1):76-88
pubmed: 34857420
Vaccine. 2008 Aug 19;26 Suppl 10:K76-86
pubmed: 18847560
Infect Agent Cancer. 2012 Dec 29;7(1):38
pubmed: 23273245
Am J Epidemiol. 2014 Sep 1;180(5):545-55
pubmed: 25081182
Lancet. 2009 Jul 25;374(9686):301-14
pubmed: 19586656
Int J Gynaecol Obstet. 2017 Jul;138 Suppl 1:7-14
pubmed: 28691329
J Natl Cancer Inst. 2015 Oct 04;108(1):
pubmed: 26438574
Value Health. 2021 Jan;24(1):61-66
pubmed: 33431154
BMJ Glob Health. 2020 Oct;5(10):
pubmed: 33082132
N Engl J Med. 2007 May 10;356(19):1928-43
pubmed: 17494926
Proc Natl Acad Sci U S A. 2020 Sep 8;117(36):22035-22041
pubmed: 32820077
Lancet Infect Dis. 2021 Nov;21(11):1598-1610
pubmed: 34245682
Lancet. 2006 Nov 11;368(9548):1706-28
pubmed: 17098090
Lancet Infect Dis. 2020 May;20(5):546
pubmed: 32311326
Vaccine. 2020 Feb 5;38(6):1302-1314
pubmed: 31870572
Lancet Child Adolesc Health. 2020 May;4(5):397-404
pubmed: 32272089
Vaccine. 2018 Aug 6;36(32 Pt A):4823-4829
pubmed: 29807710
Lancet. 2020 Feb 22;395(10224):575-590
pubmed: 32007141
Demography. 2005 Feb;42(1):1-22
pubmed: 15782893
Lancet Glob Health. 2022 Oct;10(10):e1473-e1484
pubmed: 36113531
Vaccine. 2018 Aug 6;36(32 Pt A):4761-4767
pubmed: 29580641
N Engl J Med. 2015 Feb 19;372(8):711-23
pubmed: 25693011
Lancet Oncol. 2021 Nov;22(11):1518-1529
pubmed: 34634254
Emerg Infect Dis. 2016 Jan;22(1):18-23
pubmed: 26691673
Wkly Epidemiol Rec. 2014 Oct 24;89(43):465-91
pubmed: 25346960
Lancet Glob Health. 2020 Apr;8(4):e536-e544
pubmed: 32105613
Lancet Oncol. 2010 Nov;11(11):1048-56
pubmed: 20952254
J Infect Dis. 2016 Jun 1;213(11):1694-700
pubmed: 26908738
Int Braz J Urol. 2020 Jul;46(suppl.1):104-112
pubmed: 32550703
J Natl Cancer Inst. 2012 Nov 21;104(22):1712-23
pubmed: 23104323
Lancet. 2020 Feb 22;395(10224):591-603
pubmed: 32007142
Lancet Glob Health. 2014 Jul;2(7):e406-14
pubmed: 25103394
Lancet Public Health. 2020 Apr;5(4):e213-e222
pubmed: 32057315
Ann Intern Med. 2020 Jan 7;172(1):22-29
pubmed: 31816629
Lancet Glob Health. 2020 Feb;8(2):e180-e190
pubmed: 31862245
J Infect Dis. 2016 Sep 1;214(5):685-8
pubmed: 27234416
Vaccine. 2010 May 28;28(24):4091-102
pubmed: 19909831
Lancet. 2019 Aug 10;394(10197):497-509
pubmed: 31255301
Lancet Oncol. 2019 Mar;20(3):394-407
pubmed: 30795950
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
BMJ. 2015 Jan 06;350:g7584
pubmed: 25567037
BMC Med. 2013 Jan 30;11:23
pubmed: 23363734
Expert Rev Vaccines. 2020 Aug;19(8):687-690
pubmed: 32758031
PLoS Med. 2021 Mar 11;18(3):e1003534
pubmed: 33705382